poisar

Stocks · News reference

Johnson & Johnson Highlights Hematology Portfolio at ASH 2026

Johnson & Johnson is presenting its latest hematology research and innovation at the 2026 American Society of Hematology (ASH) Annual Meeting.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

JNJ
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Brendan Coffey

    Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

    The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.

    JNJLLYABBVMCK
  2. Prosper Junior Bakiny

    Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?

    Johnson & Johnson is positioned to achieve double-digit sales growth by 2030 following its consumer health spinoff. Despite facing a major patent cliff with Stelara losing exclusivity in 2025, the company's new drug launches (Icotyde, Inlexzo, Lazcluze, Imaavy) with peak sales potential exceeding $5 billion each, combined with its robotic surgery device Ottava and strong dividend history as a Dividend King, make it an attractive investment for long-term income seekers.

    JNJ
  3. Delveinsight

    Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

    The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.

    PFEWSTBDXJNJABBV
  4. Benzinga Insights

    Cyclicals Lead Sectors In Wednesday Trading As Defensives Trail

    Five sectors are higher and six are lower in Wednesday's regular session, with cyclical sectors holding two of the top three positions. Technology sits well clear of the rest, separated from the next sector by a margin several times wider than any other gap in the table.

    AMZNAVGOCATDIAEOG
  6. Prosper Junior Bakiny

    Stocks Fell After the Midterms. History Says the Next 12 Months Could Be Very Different

    U.S. stock markets declined following midterm elections due to voter opposition to data center expansion plans and concerns about AI regulation. However, historical data shows the S&P 500 has averaged ~15% returns in the 12 months following midterm elections since 1950. The article recommends staying calm, maintaining long-term positions, and considering investments in broad market index funds, undervalued stocks, and defensive healthcare stocks.

    VOONFLXJNJ